RGD-targeted Auristatin-albumin conjugates (Seattle Genetics/Groningen University)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameRGD-targeted Auristatin-albumin conjugates (Seattle Genetics/Groningen University)
Drug Alias NameRGD-targeted MMAE-albumin conjugates (Seattle Genetics/GUIDE)RGD-targeted vedotin-albumin conjugates (Seattle Genetics/GUIDE)
ClassificationBiologics
Mechanisms of ActionIntegrin alpha-V/beta-3 modulatorsSerum albumin modulators
TargetsSerum albuminIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRijksuniversiteit te GroningenSeagen Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A